BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34311790)

  • 1. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
    J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
    Smith KE; Staton M
    Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
    [No Abstract]   [Full Text] [Related]  

  • 3. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
    Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
    Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
    Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
    Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
    Zaurova M; Hoffman RS; Vlahov D; Manini AF
    J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
    Alam RM; Keating JJ
    Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
    Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
    Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Feb; 166():. PubMed ID: 36752668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
    Waters ML; Dargan PI; Yates C; Dines AM; Eyer F; Giraudon I; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Anseeuw K; Badaras R; Bitel M; Bonnici J; Brvar M; Caganova B; Calýskan F; Ceschi A; Chamoun K; Daveloose L; Galicia M; Gartner B; Gorozia K; Grenc D; Gresnigt FMJ; Hondebrink L; Jürgens G; Konstari J; Kutubidze S; Laubner G; Liakoni E; Liguts V; Lyphout C; McKenna R; Mégarbane B; Moughty A; Nitescu GV; Noseda R; O'Connor N; Paasma R; Ortega Perez J; Perminas M; Persett PS; Põld K; Puchon E; Puiguriguer J; Radenkova-Saeva J; Rulisek J; Samer C; Schmid Y; Scholz I; Stašinskis R; Surkus J; Van den Hengel-Koot I; Vigorita F; Vogt S; Waldman W; Waring WS; Zacharov S; Zellner T; Wood DM
    Clin Toxicol (Phila); 2024 Jun; ():1-7. PubMed ID: 38934347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
    Hobbs M; Kalk NJ; Morrison PD; Stone JM
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.